在收入丰厚和股息宣布后,投资者在Regeneron提升了股票持有量。 Investors boost holdings in Regeneron after strong earnings and dividend announcement.

Kornitzer资本管理公司和其他投资者增加了其在Regeneron制药公司的股份。 Kornitzer Capital Management Inc. and other investors have increased their holdings in Regeneron Pharmaceuticals. 生物制药公司报告,每股收入为12.07美元,打人估计,并宣布季度红利为0.88美元。 The biopharmaceutical company reported earnings of $12.07 per share, beating estimates, and declared a quarterly dividend of $0.88. Regeneron以其治疗各种眼病的EYLEA注射而闻名,拥有机构投资者拥有其83.31%的股票。 Regeneron, known for its EYLEA injection for treating various eye diseases, has institutional investors owning 83.31% of its stock. 股票开放额为685.66美元,共识评级为“机动购买”,价格目标为973.13美元。 Shares opened at $685.66, with a consensus rating of "Moderate Buy" and a price target of $973.13.